scorecardresearch
Monday, November 4, 2024
TopicBharat Biotech

Topic: Bharat Biotech

‘Well-tolerated, no serious adverse events’ — Lancet publishes Covaxin’s phase 1 trial data

A preprint of the results were released last month, which revealed that all three vaccine formulations in the trial resulted in 'robust immune responses'.

Vaccine solidarity? How rich nations used political, economic clout to get ahead in queue

A look at the vaccine acquisition numbers raises serious doubt about global solidarity in Covid-19 resistance.

Even if Covaxin doesn’t meet efficacy mark, govt has no plan to re-vaccinate those taking it

Health ministry officials say there is no precedent for using a second vaccine, even as efficacy data is awaited on Bharat Biotech’s indigenous shot.

Covaxin, Covishield not for everyone — manufacturers list who should avoid the Covid vaccines

Both Bharat Biotech and SII released factsheets indicating which categories of people should be exempted from the list of beneficiaries. See the full list here.

Bharat Biotech secures Letter of Comfort from govt for additional 45 lakh vaccine doses

Out of the 45 lakh doses, over 8 lakh will be supplied to friendly countries such as Mauritius, Philippines and Myanmar, free of cost as a goodwill gesture.

Hesitancy persists over Covaxin but doctors still take shots as ‘vaccination the only way out’

Doctors in Assam, Maharashtra, Haryana say there’s no reason to not take Covaxin. But some AIIMS doctors in Delhi say they want to wait for the safety and efficacy data.

Bharat Biotech to pay compensation if Covaxin causes side effects in recipients

In the consent form, the Covaxin manufacturer said the compensation will be paid in case if the serious adverse effect is proven to be causally related to the vaccine.

SII & Bharat Biotech could see profits on low costs as India rolls out Covid vaccination

Analysts say supply to government amid low distribution, marketing and R&D costs could aid profits. Bharat Biotech vaccine is priced at Rs 206 per dose while SII’s is at Rs 200.

India plans to offer 20 million doses of Covid-19 vaccine to its neighbours

Govt firm will buy vaccines from Serum Institute of India & Bharat Biotech and supply them to Nepal, Bangladesh, Sri Lanka, Afghanistan, Seychelles and Mauritius.

‘Thought I was getting vaccine’ — Bhopal Covaxin trial site accused of misleading participants

People's University of Bhopal, the trial site, denies the claim that participants have been kept in the dark about the nature of the exercise, and say all checks and balances are in place.

On Camera

Trudeau is nursing snakes in his own backyard. Misguided Sikhs in Canada are losing the plot

By turning a blind eye to the snakes in his own backyard, Trudeau is setting the stage for a disaster of epic proportions for his country, his people, and the world at large.

Watch CutTheClutter: Flattening INR-USD rate, and debate on pros and cons of a ‘strong’ rupee

In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.

India carries out 1st patrol in Depsang since disengagement with China, to take things ‘slow’

While there are patrolling points (PP) 10, 11, 12, 12A and 13 in the Depsang Plains, the patrol in the region Monday was carried out to only one point as decided by India and China.

Xi wanted to teach India about imbalance of power. We should take a budgetary lesson from it

While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.